These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

153 related items for PubMed ID: 32997825

  • 1. VEGFR2 and VEGFA polymorphisms are not associated with an inferior prognosis in Caucasian patients with aggressive B-cell lymphoma.
    Kaddu-Mulindwa D, Rosolowski M, Ziepert M, Regitz E, Assmann G, Bewarder M, Held G, Pfreundschuh M, Bittenbring JT.
    Eur J Haematol; 2021 Jan; 106(1):100-104. PubMed ID: 32997825
    [Abstract] [Full Text] [Related]

  • 2. VEGFA and VEGFR2 genetic polymorphisms and survival in patients with diffuse large B cell lymphoma.
    Kim MK, Suh C, Chi HS, Cho HS, Bae YK, Lee KH, Lee GW, Kim IS, Eom HS, Kong SY, Bae SH, Ryoo HM, Shin IH, Mun YC, Chung H, Hyun MS.
    Cancer Sci; 2012 Mar; 103(3):497-503. PubMed ID: 22129133
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Clinical relevance of vascular endothelial growth factor (VEGFA) and VEGF receptor (VEGFR2) gene polymorphism on the treatment outcome following imatinib therapy.
    Kim DH, Xu W, Kamel-Reid S, Liu X, Jung CW, Kim S, Lipton JH.
    Ann Oncol; 2010 Jun; 21(6):1179-1188. PubMed ID: 19875757
    [Abstract] [Full Text] [Related]

  • 5. Clinical relevance of vascular endothelial growth factor type A (VEGFA) and VEGF receptor type 2 (VEGFR2) gene polymorphism in chronic lymphocytic leukemia.
    Góra-Tybor J, Szemraj J, Robak T, Jamroziak K.
    Blood Cells Mol Dis; 2015 Feb; 54(2):139-43. PubMed ID: 25488616
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Lymphoma cell VEGFR2 expression detected by immunohistochemistry predicts poor overall survival in diffuse large B cell lymphoma treated with immunochemotherapy (R-CHOP).
    Gratzinger D, Advani R, Zhao S, Talreja N, Tibshirani RJ, Shyam R, Horning S, Sehn LH, Farinha P, Briones J, Lossos IS, Gascoyne RD, Natkunam Y.
    Br J Haematol; 2010 Jan; 148(2):235-44. PubMed ID: 19821819
    [Abstract] [Full Text] [Related]

  • 8. FCGR3A gene polymorphisms may correlate with response to frontline R-CHOP therapy for diffuse large B-cell lymphoma.
    Kim DH, Jung HD, Kim JG, Lee JJ, Yang DH, Park YH, Do YR, Shin HJ, Kim MK, Hyun MS, Sohn SK.
    Blood; 2006 Oct 15; 108(8):2720-5. PubMed ID: 16609067
    [Abstract] [Full Text] [Related]

  • 9. The genotype of MLH1 identifies a subgroup of follicular lymphoma patients who do not benefit from doxorubicin: FIL-FOLL study.
    Rossi D, Bruscaggin A, La Cava P, Galimberti S, Ciabatti E, Luminari S, Rigacci L, Tucci A, Pulsoni A, Bertoldero G, Vallisa D, Rusconi C, Spina M, Arcaini L, Angrilli F, Stelitano C, Merli F, Gaidano G, Federico M, Palumbo GA.
    Haematologica; 2015 Apr 15; 100(4):517-24. PubMed ID: 25596266
    [Abstract] [Full Text] [Related]

  • 10. Angiogenesis' related genetic variants alter clinical features and prognosis of diffuse large B-cell lymphoma patients.
    Brito ABC, Delamain MT, Fanelli MF, Soares FA, de Souza CA, Vassallo J, Lima CSP.
    Tumour Biol; 2021 Apr 15; 43(1):129-140. PubMed ID: 34219681
    [Abstract] [Full Text] [Related]

  • 11. Prospective validation of candidate SNPs of VEGF/VEGFR pathway in metastatic colorectal cancer patients treated with first-line FOLFIRI plus bevacizumab.
    Loupakis F, Cremolini C, Yang D, Salvatore L, Zhang W, Wakatsuki T, Bohanes P, Schirripa M, Benhaim L, Lonardi S, Antoniotti C, Aprile G, Graziano F, Ruzzo A, Lucchesi S, Ronzoni M, De Vita F, Tonini G, Falcone A, Lenz HJ.
    PLoS One; 2013 Apr 15; 8(7):e66774. PubMed ID: 23861747
    [Abstract] [Full Text] [Related]

  • 12. Genetic Variants of VEGF (rs201963 and rs3025039) and KDR (rs7667298, rs2305948, and rs1870377) Are Associated with Glioma Risk in a Han Chinese Population: a Case-Control Study.
    Zhang J, Yang J, Chen Y, Mao Q, Li S, Xiong W, Lin Y, Chen J, Ge J.
    Mol Neurobiol; 2016 May 15; 53(4):2610-8. PubMed ID: 26093379
    [Abstract] [Full Text] [Related]

  • 13. Six versus eight doses of rituximab in patients with aggressive B cell lymphoma receiving six cycles of CHOP: results from the "Positron Emission Tomography-Guided Therapy of Aggressive Non-Hodgkin Lymphomas" (PETAL) trial.
    Hüttmann A, Rekowski J, Müller SP, Hertenstein B, Franzius C, Mesters R, Weckesser M, Kroschinsky F, Kotzerke J, Ganser A, Bengel FM, La Rosée P, Freesmeyer M, Höffkes HG, Hertel A, Behringer D, Prange-Krex G, Griesshammer M, Holzinger J, Wilop S, Krohn T, Raghavachar A, Maschmeyer G, Brink I, Schroers R, Gaska T, Bernhard H, Giagounidis A, Schütte J, Dienst A, Hautzel H, Naumann R, Klein A, Hahn D, Pöpperl G, Grube M, Marienhagen J, Schwarzer A, Kurch L, Höhler T, Steiniger H, Nückel H, Südhoff T, Römer W, Brinkmann M, Ose C, Alashkar F, Schmitz C, Dürig J, Hoelzer D, Jöckel KH, Klapper W, Dührsen U.
    Ann Hematol; 2019 Apr 15; 98(4):897-907. PubMed ID: 30610279
    [Abstract] [Full Text] [Related]

  • 14. Obesity negatively impacts outcome in elderly female patients with aggressive B-cell lymphomas treated with R-CHOP: results from prospective trials of the German high grade non-Hodgkin's lymphoma trial group.
    Hohloch K, Altmann B, Pfreundschuh M, Loeffler M, Schmitz N, Zettl F, Ziepert M, Trümper L.
    Br J Haematol; 2018 Jan 15; 180(2):236-245. PubMed ID: 29193018
    [Abstract] [Full Text] [Related]

  • 15. Sole rearrangement but not amplification of MYC is associated with a poor prognosis in patients with diffuse large B cell lymphoma and B cell lymphoma unclassifiable.
    Landsburg DJ, Falkiewicz MK, Petrich AM, Chu BA, Behdad A, Li S, Medeiros LJ, Cassaday RD, Reddy NM, Bast MA, Vose JM, Kruczek KR, Smith SE, Patel P, Hernandez-Ilizaliturri F, Karmali R, Rajguru S, Yang DT, Maly JJ, Blum KA, Zhao W, Vanslambrouck C, Nabhan C.
    Br J Haematol; 2016 Nov 15; 175(4):631-640. PubMed ID: 27469075
    [Abstract] [Full Text] [Related]

  • 16. The impact of Fc-γ receptor polymorphisms in elderly patients with diffuse large B-cell lymphoma treated with CHOP with or without rituximab.
    Ahlgrimm M, Pfreundschuh M, Kreuz M, Regitz E, Preuss KD, Bittenbring J.
    Blood; 2011 Oct 27; 118(17):4657-62. PubMed ID: 21900198
    [Abstract] [Full Text] [Related]

  • 17. Combination of ibrutinib with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) for treatment-naive patients with CD20-positive B-cell non-Hodgkin lymphoma: a non-randomised, phase 1b study.
    Younes A, Thieblemont C, Morschhauser F, Flinn I, Friedberg JW, Amorim S, Hivert B, Westin J, Vermeulen J, Bandyopadhyay N, de Vries R, Balasubramanian S, Hellemans P, Smit JW, Fourneau N, Oki Y.
    Lancet Oncol; 2014 Aug 27; 15(9):1019-26. PubMed ID: 25042202
    [Abstract] [Full Text] [Related]

  • 18. The Effect of FcγRIIIA Gene Polymorphism on the Treatment of Diffuse Large B-cell Non-Hodgkin Lymphoma: A Multicenter Prospective Observational Study.
    Büyükkurt N, Özcan MA, Ergene Ü, Payzın B, Tunalı S, Demirkan F, Özsan H, Pişkin Ö, Ündar B.
    Turk J Haematol; 2015 Jun 27; 32(2):152-7. PubMed ID: 26316483
    [Abstract] [Full Text] [Related]

  • 19. Diffuse large B-cell lymphoma with concurrent hepatitis B virus infection in the MabThera era: Unique clinical features and worse outcomes.
    Yan X, Zhou M, Lou Z, Mu Q, Sheng L, Zhang P, Wang Y, Ouyang G.
    J Cancer Res Ther; 2018 Jun 27; 14(Supplement):S248-S253. PubMed ID: 29578182
    [Abstract] [Full Text] [Related]

  • 20. Prognostic significance of maximum tumour (bulk) diameter in young patients with good-prognosis diffuse large-B-cell lymphoma treated with CHOP-like chemotherapy with or without rituximab: an exploratory analysis of the MabThera International Trial Group (MInT) study.
    Pfreundschuh M, Ho AD, Cavallin-Stahl E, Wolf M, Pettengell R, Vasova I, Belch A, Walewski J, Zinzani PL, Mingrone W, Kvaloy S, Shpilberg O, Jaeger U, Hansen M, Corrado C, Scheliga A, Loeffler M, Kuhnt E, MabThera International Trial (MInT) Group.
    Lancet Oncol; 2008 May 27; 9(5):435-44. PubMed ID: 18400558
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.